Lipid multiparticulate (LMP) technology has the capacity to combine a breadth of functionality with a range of finished dosage formats: capsules, sachets, suspensions and tablets. This technical brief describes Lonza's novel LMP technology, which is based on a proprietary melt-spray-congeal process. This innovative drug delivery approach, which has market precedence, can be used for taste-masking, extended release, and bioavailability enhancement for pharmaceutical, health and nutritional products. To learn more, please read our technical brief.
You may also be interested in:
Latest briefing from the Knowledge Center